Dr. Roberto Iacone, an accomplished biotech entrepreneur and expert in kidney therapeutics, joined Senya’s Board as a Non-Executive Director.

Dr. Iacone co-founded Alentis Therapeutics and served as its CEO until 2025. He raised $366M and led the company to the late clinical stage. Previously, Dr. Iacone co-founded Bright Peak Therapeutics and Ridgeline Therapeutics. Roberto was Head of Rare Diseases Research at Roche.